Agios’ Current Valuation Reflects Many Of The Anticipated Positives, Says Roth Capital
In a research report released Monday, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral rating and a price target of $114.00, which implies an upside of 6.5% from current levels.
Chattopadhyay commented, “We initiate coverage of AGIO shares with a Neutral. We believe, Agios’ pioneering efforts are changing the treatment landscape for a subset of AML patients and could expand to some solid tumors over the near future. Importantly, Agios has also successfully deployed its insights in metabolism to target genetic disorders.”
“However, targeting cancer metabolism is more complex than kinase signaling, which could impact the pace of future discoveries, and the current valuation reflects many of the anticipated positives.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 5.8% and a 47.6% success rate. Chattopadhyay is ranked #837 out of 3427 analysts.